Latest News
Entrada Therapeutics, Inc.
- Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
- Entrada Therapeutics Appoints Linea Aspesi Chief People Officer to Support Pipeline Growth
- Entrada Therapeutics, Inc. Announces Appointment of Linea Aspesi as Chief People Officer
- Entrada Therapeutics names Linea Aspesi as chief people officer By Investing.com
- Entrada Therapeutics names Linea Aspesi as Chief People Officer
- Why Did Entrada Therapeutics (NASDAQ:TRDA) Surge 10.07% on Monday? The Catalyst, the Fundamentals and What Comes Next
- Entrada Therapeutics reports positive Phase 1/2 results for Duchenne muscular dystrophy drug ENTR-601-45
- Entrada Therapeutics Reports Phase 1/2 Data for ENTR-601-45 in DMD Exon 45 Skipping
- Entrada Therapeutics clears DMC review, advances DMD study to top dose
- Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
- Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity
- Entrada Therapeutics rated Buy with $8.50 targe...
Headlines from the last 30 days, linking to the original publishers. See all market news →